KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Elevance Health (ELV) over the last 17 years, with Q4 2025 value amounting to -$209.0 million.

  • Elevance Health's Free Cash Flow fell 15442.71% to -$209.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year decrease of 3027.24%. This contributed to the annual value of $3.2 billion for FY2025, which is 3027.24% down from last year.
  • Latest data reveals that Elevance Health reported Free Cash Flow of -$209.0 million as of Q4 2025, which was down 15442.71% from $775.0 million recorded in Q3 2025.
  • In the past 5 years, Elevance Health's Free Cash Flow registered a high of $6.2 billion during Q1 2023, and its lowest value of -$3.3 billion during Q4 2023.
  • Moreover, its 5-year median value for Free Cash Flow was $1.6 billion (2023), whereas its average is $1.5 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 23633.63% in 2022, then soared by 134112.9% in 2025.
  • Elevance Health's Free Cash Flow (Quarter) stood at $1.3 billion in 2021, then crashed by 236.34% to -$1.8 billion in 2022, then tumbled by 81.55% to -$3.3 billion in 2023, then surged by 111.65% to $384.0 million in 2024, then tumbled by 154.43% to -$209.0 million in 2025.
  • Its Free Cash Flow stands at -$209.0 million for Q4 2025, versus $775.0 million for Q3 2025 and $1.8 billion for Q2 2025.